Coherus Oncology, Inc. (CHRS)

Coherus Oncology Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 20, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	87	159	371	778	1,225	1,252
Market Cap Growth	-65.28%	-57.13%	-52.31%	-36.55%	-2.13%	-0.83%
Enterprise Value	304	361	718	971	1,176	1,166
Last Close Price	0.75	1.38	3.33	7.92	15.96	17.38
PE Ratio	1.75	5.58	-	-	-	9.47
Forward PE	-	-	-	-	-	16.86
PS Ratio	0.32	0.60	1.44	3.68	3.75	2.63
PB Ratio	-	-1.20	-1.92	-5.66	12.54	4.46
P/TBV Ratio	-	-	-	-	13.02	4.51
P/FCF Ratio	173.25	-	-	-	-	8.52
P/OCF Ratio	173.25	-	-	-	-	8.12
EV/Sales Ratio	1.12	1.35	2.79	4.60	3.60	2.45
EV/EBITDA Ratio	-	-	-	-	-	7.32
EV/EBIT Ratio	-	-	-	-	-	7.46
EV/FCF Ratio	607.43	-	-	-	-	7.93
Debt / Equity Ratio	-1.63	-2.26	-2.49	-3.50	4.29	1.48
Debt / EBITDA Ratio	-	-	-	-	-	2.57
Debt / FCF Ratio	599.00	-	-	-	-	2.84
Asset Turnover	0.48	0.50	0.46	0.36	0.43	0.76
Inventory Turnover	3.63	1.77	3.14	1.83	1.41	1.39
Quick Ratio	0.57	0.88	1.14	2.17	3.27	4.79
Current Ratio	1.22	1.21	1.43	2.75	3.64	5.27
Return on Equity (ROE)	-	-	-	-	-151.62%	68.49%
Return on Assets (ROA)	-9.10%	-10.94%	-21.75%	-27.68%	-21.68%	15.63%
Return on Capital (ROIC)	-20.04%	-25.98%	-38.31%	-37.35%	-27.15%	19.66%
Return on Capital Employed (ROCE)	-	-	-	-	-	22.50%
Earnings Yield	-151.15%	17.93%	-64.15%	-37.52%	-23.43%	10.56%
FCF Yield	0.58%	-12.86%	-47.16%	-31.01%	-3.16%	11.73%
Buyback Yield / Dilution	-12.48%	-21.95%	-21.30%	-2.89%	9.63%	-14.08%

Updated May 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q